Neurological updates: neurological complications of CAR-T therapy

Tallantyre, Emma ORCID: https://orcid.org/0000-0002-3760-6634, Evans, Nia, Parry-Jones, Jack, Morgan, Matt, Jones, Ceri and Ingram, Wendy 2021. Neurological updates: neurological complications of CAR-T therapy. Journal of Neurology 268 , pp. 1544-1554. 10.1007/s00415-020-10237-3

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (1MB) | Preview

Abstract

Chimeric antigen receptor (CAR) expressing T-cells now offer an effective treatment option for people with previously refractory B-cell malignancies and are under development for a wide range of other tumours. However, neurological toxicity is a common complication of CAR T-cell therapy, seen in over 50% of recipients in some cohorts. Since 2018, the term immune effector cell-associated neurotoxicity syndrome (ICANS) has been used to describe and grade neurotoxicity seen after CAR T-cells and other similar therapies. ICANS following CAR-T therapy is usually self-limiting but can necessitate admission to the intensive care unit and is rarely fatal. As CAR-T therapies enter routine clinical practice, it is important for neurologists to be aware of the nature of neurological complications. Here we summarise the clinical manifestations, mechanisms, investigations and recommended treatment of CAR-T related neurotoxicity, focusing on the licensed CD19 products.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine Neuroscience and Mental Health Research Institute (NMHRI)
Additional Information:	This article is licensed under a Creative Commons Attribution 4.0 International License
Publisher:	Springer
ISSN:	0340-5354
Date of First Compliant Deposit:	6 October 2020
Date of Acceptance:	18 September 2020
Last Modified:	04 May 2023 23:28
URI:	https://orca.cardiff.ac.uk/id/eprint/135340

Citation Data

Cited 13 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item